Skip to main content

Advertisement

Table 3 Percent actuarial survival outcomes and control rates

From: Dose escalation with stereotactic body radiation therapy boost for locally advanced non small cell lung cancer

Median Followup (range in months) 14 (1–36)
Local control at 1 year, at 14 months, (failed/controlled) 76%, 76% (3/13)
Regional control at 1 year, at 14 months, (failed/controlled) 79%, 68% (6/10)
Distant control at 1 year, at 14 months, (failed/controlled) 71%, 61.5% (5/11)
PFS at 1 year, at 14 months (progression/no progression) 42%, 32% (10/6)
Overall survival at 1 year, at 14 months (dead/alive) 78%, 78%, (4/12)